| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 41 | 2022 | 272 | 5.490 |
Why?
|
| Clinical Trials as Topic | 29 | 2018 | 848 | 3.740 |
Why?
|
| Minority Groups | 10 | 2021 | 196 | 3.050 |
Why?
|
| Patient Selection | 10 | 2021 | 592 | 2.060 |
Why?
|
| Severity of Illness Index | 31 | 2017 | 1851 | 1.840 |
Why?
|
| Cultural Diversity | 4 | 2018 | 67 | 1.400 |
Why?
|
| Tissue Plasminogen Activator | 21 | 2017 | 296 | 1.340 |
Why?
|
| Health Behavior | 7 | 2016 | 458 | 1.320 |
Why?
|
| Colorectal Neoplasms | 11 | 2010 | 560 | 1.270 |
Why?
|
| Research Subjects | 3 | 2018 | 45 | 1.200 |
Why?
|
| Trust | 3 | 2021 | 75 | 1.200 |
Why?
|
| Markov Chains | 3 | 2016 | 133 | 1.150 |
Why?
|
| Research Design | 14 | 2020 | 729 | 1.090 |
Why?
|
| Mass Screening | 8 | 2010 | 837 | 1.060 |
Why?
|
| Disability Evaluation | 10 | 2015 | 298 | 1.040 |
Why?
|
| Humans | 182 | 2022 | 68525 | 1.030 |
Why?
|
| Bayes Theorem | 3 | 2016 | 303 | 0.970 |
Why?
|
| Erythrocyte Transfusion | 5 | 2020 | 72 | 0.920 |
Why?
|
| Brain Injuries | 6 | 2016 | 268 | 0.910 |
Why?
|
| Attitude to Health | 6 | 2013 | 403 | 0.850 |
Why?
|
| Middle Aged | 96 | 2020 | 21119 | 0.840 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2022 | 929 | 0.820 |
Why?
|
| Antiparkinson Agents | 8 | 2022 | 34 | 0.800 |
Why?
|
| Automobiles | 8 | 2007 | 26 | 0.780 |
Why?
|
| Male | 106 | 2020 | 37281 | 0.780 |
Why?
|
| Surveys and Questionnaires | 20 | 2015 | 2798 | 0.760 |
Why?
|
| Erythropoietin | 4 | 2016 | 96 | 0.760 |
Why?
|
| Societies, Medical | 6 | 2016 | 403 | 0.730 |
Why?
|
| Female | 104 | 2020 | 38015 | 0.710 |
Why?
|
| Anemia | 3 | 2014 | 104 | 0.700 |
Why?
|
| Cerebrovascular Disorders | 8 | 2014 | 182 | 0.690 |
Why?
|
| Hospital Mortality | 8 | 2020 | 384 | 0.690 |
Why?
|
| Stroke | 19 | 2017 | 2161 | 0.690 |
Why?
|
| Arthritis, Rheumatoid | 10 | 2004 | 155 | 0.690 |
Why?
|
| Biomedical Research | 2 | 2017 | 310 | 0.680 |
Why?
|
| Feeding Behavior | 4 | 2015 | 224 | 0.660 |
Why?
|
| Movement Disorders | 5 | 2012 | 58 | 0.660 |
Why?
|
| Intention | 3 | 2010 | 78 | 0.650 |
Why?
|
| National Institutes of Health (U.S.) | 11 | 2017 | 109 | 0.630 |
Why?
|
| Inservice Training | 1 | 2018 | 68 | 0.620 |
Why?
|
| Aged | 63 | 2017 | 14842 | 0.620 |
Why?
|
| Research Personnel | 1 | 2018 | 83 | 0.610 |
Why?
|
| Creatine | 7 | 2017 | 30 | 0.610 |
Why?
|
| Hemoglobins | 2 | 2014 | 120 | 0.610 |
Why?
|
| Disease Progression | 12 | 2017 | 1037 | 0.600 |
Why?
|
| Psychometrics | 8 | 2016 | 514 | 0.580 |
Why?
|
| Models, Psychological | 2 | 2015 | 180 | 0.570 |
Why?
|
| Brain Ischemia | 13 | 2015 | 665 | 0.570 |
Why?
|
| Occupational Health Services | 5 | 2000 | 14 | 0.570 |
Why?
|
| Biobehavioral Sciences | 1 | 2016 | 2 | 0.570 |
Why?
|
| Blood Transfusion | 6 | 2020 | 205 | 0.560 |
Why?
|
| Plasminogen Activators | 5 | 2001 | 19 | 0.560 |
Why?
|
| Data Interpretation, Statistical | 6 | 2020 | 329 | 0.560 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2009 | 467 | 0.550 |
Why?
|
| Multicenter Studies as Topic | 9 | 2022 | 186 | 0.540 |
Why?
|
| Referral and Consultation | 3 | 2018 | 383 | 0.530 |
Why?
|
| Health Status Indicators | 3 | 2007 | 117 | 0.530 |
Why?
|
| Patient Education as Topic | 5 | 2004 | 424 | 0.530 |
Why?
|
| Postural Balance | 2 | 2013 | 93 | 0.530 |
Why?
|
| Statistics as Topic | 3 | 2012 | 219 | 0.530 |
Why?
|
| Wounds and Injuries | 5 | 2017 | 334 | 0.520 |
Why?
|
| Adult | 62 | 2020 | 21375 | 0.520 |
Why?
|
| Hemorrhage | 5 | 2020 | 328 | 0.510 |
Why?
|
| Self Care | 3 | 2004 | 252 | 0.490 |
Why?
|
| Informed Consent | 3 | 2016 | 127 | 0.490 |
Why?
|
| Treatment Outcome | 39 | 2022 | 7028 | 0.490 |
Why?
|
| Factor Analysis, Statistical | 5 | 2012 | 201 | 0.470 |
Why?
|
| Health Knowledge, Attitudes, Practice | 10 | 2010 | 766 | 0.470 |
Why?
|
| Sensation Disorders | 1 | 2013 | 14 | 0.460 |
Why?
|
| United States | 28 | 2017 | 7335 | 0.450 |
Why?
|
| Fibrinolytic Agents | 9 | 2014 | 377 | 0.440 |
Why?
|
| Societies, Scientific | 1 | 2012 | 18 | 0.440 |
Why?
|
| Diabetes Mellitus | 5 | 2006 | 693 | 0.420 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2011 | 58 | 0.410 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2013 | 86 | 0.410 |
Why?
|
| Patient Participation | 3 | 2016 | 145 | 0.410 |
Why?
|
| Blood Component Transfusion | 3 | 2016 | 11 | 0.410 |
Why?
|
| Neuropsychological Tests | 5 | 2014 | 517 | 0.410 |
Why?
|
| Neurologic Examination | 6 | 2014 | 107 | 0.400 |
Why?
|
| Exsanguination | 3 | 2016 | 8 | 0.400 |
Why?
|
| Likelihood Functions | 2 | 2016 | 105 | 0.390 |
Why?
|
| Pilot Projects | 7 | 2021 | 1341 | 0.390 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 442 | 0.390 |
Why?
|
| Plasma | 5 | 2020 | 58 | 0.380 |
Why?
|
| Language | 3 | 2017 | 120 | 0.370 |
Why?
|
| Resuscitation | 5 | 2020 | 77 | 0.370 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 179 | 0.360 |
Why?
|
| Caffeine | 3 | 2017 | 81 | 0.360 |
Why?
|
| Schizophrenic Psychology | 1 | 2009 | 53 | 0.350 |
Why?
|
| Health Status Disparities | 1 | 2013 | 326 | 0.350 |
Why?
|
| Diabetes Complications | 3 | 2007 | 249 | 0.340 |
Why?
|
| Follow-Up Studies | 19 | 2017 | 3256 | 0.340 |
Why?
|
| Health Services Accessibility | 5 | 2008 | 581 | 0.340 |
Why?
|
| Aged, 80 and over | 17 | 2017 | 4843 | 0.330 |
Why?
|
| Asthma | 6 | 1999 | 345 | 0.330 |
Why?
|
| Reproducibility of Results | 14 | 2016 | 2077 | 0.320 |
Why?
|
| Minocycline | 8 | 2009 | 61 | 0.320 |
Why?
|
| Mental Processes | 1 | 2008 | 22 | 0.320 |
Why?
|
| Odds Ratio | 8 | 2020 | 880 | 0.310 |
Why?
|
| Health Education | 5 | 2012 | 279 | 0.310 |
Why?
|
| Sample Size | 4 | 2012 | 79 | 0.310 |
Why?
|
| Telephone | 2 | 2009 | 160 | 0.310 |
Why?
|
| Scleroderma, Systemic | 3 | 2006 | 446 | 0.300 |
Why?
|
| Occupations | 1 | 2007 | 27 | 0.300 |
Why?
|
| Hypertension | 4 | 2007 | 1531 | 0.300 |
Why?
|
| Double-Blind Method | 19 | 2017 | 1737 | 0.300 |
Why?
|
| Cardiovascular Diseases | 2 | 2012 | 938 | 0.290 |
Why?
|
| Self-Assessment | 1 | 2007 | 69 | 0.290 |
Why?
|
| South Carolina | 9 | 2013 | 2750 | 0.290 |
Why?
|
| Advisory Committees | 1 | 2007 | 73 | 0.290 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2022 | 84 | 0.290 |
Why?
|
| Laparotomy | 2 | 2017 | 65 | 0.290 |
Why?
|
| Behavior Therapy | 1 | 2009 | 297 | 0.290 |
Why?
|
| Coronary Disease | 3 | 2007 | 358 | 0.280 |
Why?
|
| Shock, Hemorrhagic | 2 | 2017 | 33 | 0.280 |
Why?
|
| Regression Analysis | 5 | 2014 | 737 | 0.280 |
Why?
|
| Linear Models | 5 | 2020 | 521 | 0.280 |
Why?
|
| Antibodies, Antiphospholipid | 4 | 2015 | 29 | 0.280 |
Why?
|
| Prospective Studies | 9 | 2021 | 3702 | 0.280 |
Why?
|
| Neuroprotective Agents | 4 | 2011 | 317 | 0.270 |
Why?
|
| Lower Extremity | 1 | 2007 | 153 | 0.260 |
Why?
|
| Nonlinear Dynamics | 1 | 2005 | 55 | 0.260 |
Why?
|
| Risk | 3 | 2005 | 563 | 0.250 |
Why?
|
| Cross-Sectional Studies | 13 | 2016 | 2264 | 0.250 |
Why?
|
| Demography | 1 | 2005 | 279 | 0.250 |
Why?
|
| Emergency Service, Hospital | 7 | 2005 | 711 | 0.250 |
Why?
|
| Quality of Life | 9 | 2022 | 1515 | 0.250 |
Why?
|
| Health Promotion | 3 | 1999 | 407 | 0.240 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 217 | 0.240 |
Why?
|
| Logistic Models | 8 | 2014 | 1419 | 0.230 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 378 | 0.230 |
Why?
|
| Blood Platelets | 4 | 2020 | 284 | 0.230 |
Why?
|
| Oxygen | 2 | 2015 | 386 | 0.230 |
Why?
|
| Activities of Daily Living | 4 | 2013 | 319 | 0.230 |
Why?
|
| Osteoarthritis | 1 | 2004 | 73 | 0.230 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2004 | 98 | 0.230 |
Why?
|
| Recombinant Proteins | 10 | 2010 | 742 | 0.220 |
Why?
|
| Urban Health Services | 1 | 2002 | 24 | 0.220 |
Why?
|
| Algorithms | 5 | 2016 | 1194 | 0.220 |
Why?
|
| Time Factors | 18 | 2017 | 4655 | 0.220 |
Why?
|
| Workplace | 4 | 1999 | 75 | 0.220 |
Why?
|
| Living Donors | 1 | 2004 | 160 | 0.220 |
Why?
|
| Myocardial Infarction | 9 | 2015 | 807 | 0.220 |
Why?
|
| Nutritional Sciences | 2 | 2000 | 21 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2002 | 1085 | 0.210 |
Why?
|
| Risk Factors | 18 | 2015 | 5719 | 0.210 |
Why?
|
| Longitudinal Studies | 6 | 2017 | 1054 | 0.210 |
Why?
|
| Sleep Wake Disorders | 2 | 2014 | 94 | 0.200 |
Why?
|
| Cohort Studies | 11 | 2016 | 2356 | 0.200 |
Why?
|
| Electrocardiography | 6 | 2017 | 601 | 0.200 |
Why?
|
| Health Maintenance Organizations | 2 | 1999 | 22 | 0.200 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 38 | 0.190 |
Why?
|
| Osteoporosis | 2 | 1992 | 88 | 0.190 |
Why?
|
| Substance-Related Disorders | 1 | 2009 | 1241 | 0.180 |
Why?
|
| Socioeconomic Factors | 8 | 2013 | 955 | 0.180 |
Why?
|
| Patient Compliance | 5 | 2007 | 402 | 0.180 |
Why?
|
| Thrombosis | 2 | 2015 | 218 | 0.180 |
Why?
|
| ROC Curve | 2 | 2013 | 392 | 0.170 |
Why?
|
| Blood Banks | 2 | 2015 | 6 | 0.170 |
Why?
|
| Program Evaluation | 6 | 2009 | 502 | 0.170 |
Why?
|
| Cognition Disorders | 2 | 2014 | 342 | 0.170 |
Why?
|
| Acute Disease | 9 | 2014 | 658 | 0.170 |
Why?
|
| Antihypertensive Agents | 2 | 2004 | 497 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 7 | 2008 | 1026 | 0.160 |
Why?
|
| Stakeholder Participation | 1 | 2018 | 17 | 0.160 |
Why?
|
| Multivariate Analysis | 8 | 2005 | 1046 | 0.160 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2017 | 9 | 0.160 |
Why?
|
| Total Quality Management | 1 | 1997 | 45 | 0.160 |
Why?
|
| Computer Simulation | 3 | 2020 | 705 | 0.160 |
Why?
|
| Random Allocation | 2 | 2012 | 442 | 0.150 |
Why?
|
| Patient Admission | 2 | 1997 | 99 | 0.150 |
Why?
|
| Mobile Health Units | 1 | 2017 | 18 | 0.150 |
Why?
|
| Blood Chemical Analysis | 1 | 1997 | 43 | 0.150 |
Why?
|
| Triage | 2 | 1997 | 109 | 0.150 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2017 | 30 | 0.150 |
Why?
|
| Thrombolytic Therapy | 3 | 2006 | 233 | 0.150 |
Why?
|
| Health Services Research | 3 | 2007 | 209 | 0.150 |
Why?
|
| HLA-DR Antigens | 1 | 1996 | 41 | 0.150 |
Why?
|
| Intensive Care Units | 2 | 2016 | 344 | 0.150 |
Why?
|
| Occupational Health | 1 | 1997 | 41 | 0.150 |
Why?
|
| Religion and Psychology | 1 | 2016 | 15 | 0.150 |
Why?
|
| Adolescent | 14 | 2020 | 8903 | 0.140 |
Why?
|
| Abdominal Injuries | 1 | 2017 | 60 | 0.140 |
Why?
|
| Telecommunications | 1 | 2016 | 31 | 0.140 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 778 | 0.140 |
Why?
|
| Interpersonal Relations | 1 | 2018 | 209 | 0.140 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 32 | 0.140 |
Why?
|
| Clinical Protocols | 2 | 2016 | 172 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1998 | 234 | 0.140 |
Why?
|
| Religion and Medicine | 1 | 1996 | 25 | 0.140 |
Why?
|
| Intracranial Pressure | 2 | 2015 | 58 | 0.140 |
Why?
|
| Biostatistics | 1 | 2016 | 43 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 503 | 0.140 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1995 | 24 | 0.140 |
Why?
|
| Emergencies | 1 | 2016 | 107 | 0.140 |
Why?
|
| Thrombophilia | 1 | 2015 | 21 | 0.140 |
Why?
|
| Hemostasis | 3 | 2015 | 32 | 0.130 |
Why?
|
| Quality Improvement | 2 | 2017 | 413 | 0.130 |
Why?
|
| Predictive Value of Tests | 8 | 2013 | 1465 | 0.130 |
Why?
|
| Ubiquinone | 3 | 2010 | 14 | 0.130 |
Why?
|
| Empirical Research | 1 | 2015 | 12 | 0.130 |
Why?
|
| Cerebrovascular Circulation | 2 | 2015 | 296 | 0.130 |
Why?
|
| Tacrolimus | 2 | 2014 | 127 | 0.130 |
Why?
|
| Information Dissemination | 1 | 2016 | 113 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2015 | 2004 | 0.130 |
Why?
|
| Heart Rate | 1 | 2017 | 568 | 0.130 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2017 | 266 | 0.130 |
Why?
|
| Sodium Fluoride | 2 | 1991 | 9 | 0.120 |
Why?
|
| Industry | 3 | 1999 | 28 | 0.120 |
Why?
|
| Trauma Centers | 4 | 2017 | 197 | 0.120 |
Why?
|
| Antiphospholipid Syndrome | 2 | 2015 | 25 | 0.120 |
Why?
|
| Colectomy | 1 | 2014 | 64 | 0.120 |
Why?
|
| Data Collection | 3 | 2006 | 420 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2016 | 284 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 546 | 0.120 |
Why?
|
| Communication | 1 | 2016 | 329 | 0.120 |
Why?
|
| Hematinics | 1 | 2014 | 52 | 0.120 |
Why?
|
| Fatigue | 1 | 2014 | 132 | 0.120 |
Why?
|
| Survival Rate | 4 | 2015 | 1055 | 0.120 |
Why?
|
| Focus Groups | 2 | 2013 | 247 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 785 | 0.110 |
Why?
|
| Minority Health | 1 | 2013 | 14 | 0.110 |
Why?
|
| Tremor | 1 | 2013 | 16 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2012 | 105 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 168 | 0.110 |
Why?
|
| Erythrocytes | 3 | 2020 | 137 | 0.110 |
Why?
|
| Calibration | 1 | 2012 | 73 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1997 | 529 | 0.110 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2012 | 12 | 0.110 |
Why?
|
| Social Adjustment | 1 | 2012 | 74 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 36 | 0.110 |
Why?
|
| Movement | 1 | 2013 | 179 | 0.110 |
Why?
|
| Midwestern United States | 3 | 2002 | 36 | 0.110 |
Why?
|
| Hemodynamics | 1 | 2015 | 705 | 0.100 |
Why?
|
| Young Adult | 5 | 2020 | 5708 | 0.100 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2011 | 20 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2012 | 85 | 0.100 |
Why?
|
| Accidental Falls | 1 | 2012 | 84 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2013 | 368 | 0.100 |
Why?
|
| Stroke Volume | 2 | 2011 | 586 | 0.100 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 791 | 0.100 |
Why?
|
| Blood Glucose | 2 | 2006 | 631 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 2 | 2015 | 221 | 0.100 |
Why?
|
| Drug Utilization | 2 | 2009 | 119 | 0.100 |
Why?
|
| Models, Statistical | 4 | 2005 | 446 | 0.100 |
Why?
|
| Models, Structural | 1 | 1990 | 22 | 0.100 |
Why?
|
| Pain Management | 1 | 2012 | 186 | 0.090 |
Why?
|
| Research | 1 | 2011 | 214 | 0.090 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 1990 | 4 | 0.090 |
Why?
|
| Chlorophenols | 1 | 1990 | 6 | 0.090 |
Why?
|
| Herbicides | 1 | 1990 | 24 | 0.090 |
Why?
|
| Thrombomodulin | 2 | 2006 | 3 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2012 | 204 | 0.090 |
Why?
|
| Health Status | 6 | 2013 | 429 | 0.090 |
Why?
|
| Medication Adherence | 2 | 2015 | 335 | 0.090 |
Why?
|
| Self Report | 1 | 2011 | 370 | 0.090 |
Why?
|
| Sarcoma | 1 | 1990 | 70 | 0.090 |
Why?
|
| Foramen Ovale, Patent | 1 | 2009 | 21 | 0.090 |
Why?
|
| Infant, Premature | 1 | 2011 | 284 | 0.090 |
Why?
|
| Medical Futility | 2 | 2006 | 31 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2014 | 2453 | 0.090 |
Why?
|
| Telefacsimile | 1 | 2009 | 6 | 0.090 |
Why?
|
| Cerebral Hemorrhage | 3 | 2003 | 198 | 0.090 |
Why?
|
| Dopamine | 1 | 2011 | 474 | 0.090 |
Why?
|
| Pharmacies | 1 | 2009 | 18 | 0.090 |
Why?
|
| Survival Analysis | 6 | 2016 | 714 | 0.080 |
Why?
|
| Erythrocyte Count | 2 | 2020 | 14 | 0.080 |
Why?
|
| Telemedicine | 1 | 2017 | 699 | 0.080 |
Why?
|
| PubMed | 1 | 2008 | 21 | 0.080 |
Why?
|
| Reminder Systems | 1 | 2009 | 39 | 0.080 |
Why?
|
| Michigan | 4 | 2003 | 68 | 0.080 |
Why?
|
| Glasgow Outcome Scale | 3 | 2016 | 15 | 0.080 |
Why?
|
| Heart Valve Diseases | 1 | 2009 | 123 | 0.080 |
Why?
|
| Neoplasms | 2 | 2015 | 1660 | 0.080 |
Why?
|
| Blood Pressure | 3 | 2006 | 1447 | 0.080 |
Why?
|
| Propranolol | 5 | 1993 | 102 | 0.080 |
Why?
|
| Registries | 2 | 2015 | 730 | 0.080 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 306 | 0.070 |
Why?
|
| Social Support | 3 | 1998 | 423 | 0.070 |
Why?
|
| Age Factors | 5 | 2017 | 1860 | 0.070 |
Why?
|
| Community Participation | 1 | 2007 | 42 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2007 | 86 | 0.070 |
Why?
|
| Asia, Southeastern | 1 | 2006 | 5 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2005 | 1753 | 0.070 |
Why?
|
| Myelin Basic Protein | 1 | 2006 | 62 | 0.070 |
Why?
|
| North America | 2 | 2017 | 111 | 0.070 |
Why?
|
| S100 Proteins | 1 | 2006 | 42 | 0.070 |
Why?
|
| Osteoporosis, Postmenopausal | 3 | 1991 | 20 | 0.070 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2006 | 35 | 0.070 |
Why?
|
| Mentors | 1 | 2007 | 81 | 0.070 |
Why?
|
| Recurrence | 7 | 2015 | 948 | 0.070 |
Why?
|
| Nerve Growth Factors | 1 | 2006 | 75 | 0.070 |
Why?
|
| Community Networks | 1 | 2007 | 96 | 0.070 |
Why?
|
| Acculturation | 1 | 2006 | 25 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2012 | 756 | 0.070 |
Why?
|
| United Kingdom | 1 | 2006 | 152 | 0.070 |
Why?
|
| Disease Management | 2 | 2009 | 248 | 0.070 |
Why?
|
| Self Medication | 1 | 2005 | 25 | 0.070 |
Why?
|
| Nonprescription Drugs | 1 | 2005 | 28 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2009 | 1329 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2007 | 235 | 0.070 |
Why?
|
| Injury Severity Score | 2 | 2016 | 204 | 0.070 |
Why?
|
| Penicillamine | 1 | 2005 | 10 | 0.070 |
Why?
|
| Intracranial Hemorrhages | 3 | 2014 | 80 | 0.060 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2005 | 9 | 0.060 |
Why?
|
| Aging | 2 | 2007 | 911 | 0.060 |
Why?
|
| Dietary Fiber | 3 | 2000 | 37 | 0.060 |
Why?
|
| Dopamine Agents | 1 | 2005 | 56 | 0.060 |
Why?
|
| Length of Stay | 2 | 2020 | 780 | 0.060 |
Why?
|
| Life Style | 1 | 2007 | 338 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2007 | 281 | 0.060 |
Why?
|
| Biometry | 1 | 2005 | 72 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 82 | 0.060 |
Why?
|
| Retrospective Studies | 8 | 2015 | 7264 | 0.060 |
Why?
|
| Injections, Intravenous | 4 | 2010 | 215 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 107 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2005 | 1039 | 0.060 |
Why?
|
| Reference Values | 2 | 2015 | 579 | 0.060 |
Why?
|
| Educational Status | 1 | 2004 | 273 | 0.060 |
Why?
|
| Canada | 2 | 2016 | 266 | 0.060 |
Why?
|
| Child | 7 | 2014 | 6400 | 0.060 |
Why?
|
| Computational Biology | 1 | 2005 | 190 | 0.060 |
Why?
|
| Placebos | 6 | 2004 | 195 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2004 | 85 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2007 | 866 | 0.060 |
Why?
|
| Smoking | 3 | 2007 | 1449 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2006 | 434 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 648 | 0.060 |
Why?
|
| International Cooperation | 2 | 2014 | 88 | 0.060 |
Why?
|
| Doxycycline | 1 | 2003 | 49 | 0.050 |
Why?
|
| Hospitalization | 2 | 1999 | 977 | 0.050 |
Why?
|
| Global Health | 1 | 2002 | 135 | 0.050 |
Why?
|
| Incidence | 3 | 2016 | 1582 | 0.050 |
Why?
|
| Vulnerable Populations | 1 | 2002 | 84 | 0.050 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 82 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 334 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 180 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 536 | 0.050 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2022 | 124 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 1745 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2006 | 2323 | 0.050 |
Why?
|
| Spinal Fractures | 2 | 1992 | 43 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2014 | 3185 | 0.050 |
Why?
|
| Pain | 3 | 2012 | 472 | 0.050 |
Why?
|
| Urban Population | 3 | 1997 | 254 | 0.050 |
Why?
|
| Brain | 1 | 2011 | 2175 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2022 | 183 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2020 | 35 | 0.050 |
Why?
|
| Platelet Transfusion | 1 | 2020 | 21 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2020 | 218 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 1999 | 16 | 0.050 |
Why?
|
| Spinal Injuries | 2 | 1990 | 30 | 0.040 |
Why?
|
| Bone Density | 2 | 1992 | 159 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 148 | 0.040 |
Why?
|
| Self-Examination | 1 | 1999 | 6 | 0.040 |
Why?
|
| Diet, Fat-Restricted | 1 | 1999 | 6 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2004 | 445 | 0.040 |
Why?
|
| Fractures, Bone | 2 | 1990 | 132 | 0.040 |
Why?
|
| Health Surveys | 2 | 1997 | 488 | 0.040 |
Why?
|
| Software Design | 1 | 1997 | 18 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2004 | 702 | 0.040 |
Why?
|
| Medicine | 1 | 1998 | 51 | 0.040 |
Why?
|
| Specialization | 1 | 1998 | 66 | 0.040 |
Why?
|
| Israel | 1 | 2017 | 26 | 0.040 |
Why?
|
| Translating | 1 | 2017 | 23 | 0.040 |
Why?
|
| Feedback | 1 | 1997 | 90 | 0.040 |
Why?
|
| Depression | 1 | 2005 | 942 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2017 | 23 | 0.040 |
Why?
|
| Autonomic Nervous System | 1 | 2017 | 31 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 1999 | 222 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1997 | 56 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 1997 | 43 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2017 | 31 | 0.040 |
Why?
|
| Prognosis | 7 | 2000 | 2093 | 0.040 |
Why?
|
| Diet | 2 | 1999 | 513 | 0.040 |
Why?
|
| Tuberculosis, Pleural | 1 | 1996 | 2 | 0.040 |
Why?
|
| Rheumatoid Factor | 1 | 1996 | 21 | 0.040 |
Why?
|
| Health Services | 1 | 1997 | 87 | 0.040 |
Why?
|
| Empyema, Pleural | 1 | 1996 | 13 | 0.040 |
Why?
|
| Creatinine | 1 | 1997 | 243 | 0.040 |
Why?
|
| Ribs | 1 | 1996 | 25 | 0.040 |
Why?
|
| Exercise | 1 | 2022 | 657 | 0.040 |
Why?
|
| Haplotypes | 1 | 1996 | 174 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 13 | 0.040 |
Why?
|
| Epitopes | 1 | 1996 | 146 | 0.040 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1997 | 130 | 0.040 |
Why?
|
| Phosphatidylserines | 1 | 2015 | 22 | 0.030 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2015 | 10 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2015 | 621 | 0.030 |
Why?
|
| Tissue Preservation | 1 | 2015 | 44 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 65 | 0.030 |
Why?
|
| Thromboembolism | 2 | 2014 | 91 | 0.030 |
Why?
|
| Cholesterol | 1 | 1997 | 331 | 0.030 |
Why?
|
| Alleles | 1 | 1996 | 386 | 0.030 |
Why?
|
| Sigmoidoscopy | 1 | 1995 | 38 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 567 | 0.030 |
Why?
|
| Blood Preservation | 1 | 2015 | 13 | 0.030 |
Why?
|
| Autoantigens | 1 | 2015 | 91 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2015 | 15 | 0.030 |
Why?
|
| Texas | 1 | 2015 | 92 | 0.030 |
Why?
|
| Hospitals, University | 2 | 2006 | 169 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 289 | 0.030 |
Why?
|
| Videotape Recording | 1 | 1994 | 43 | 0.030 |
Why?
|
| Prednisone | 1 | 1995 | 104 | 0.030 |
Why?
|
| Persistent Vegetative State | 1 | 2014 | 5 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 785 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2015 | 103 | 0.030 |
Why?
|
| Education | 1 | 1994 | 83 | 0.030 |
Why?
|
| Aneuploidy | 1 | 1994 | 21 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 1995 | 98 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 627 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1995 | 411 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 1994 | 86 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 951 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 117 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 253 | 0.030 |
Why?
|
| Palliative Care | 1 | 2015 | 271 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 239 | 0.030 |
Why?
|
| Hydroxyproline | 1 | 1992 | 33 | 0.030 |
Why?
|
| Observation | 1 | 2012 | 30 | 0.030 |
Why?
|
| Italy | 1 | 2012 | 36 | 0.030 |
Why?
|
| Translations | 1 | 2012 | 12 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2012 | 17 | 0.030 |
Why?
|
| Medicaid | 2 | 2009 | 301 | 0.030 |
Why?
|
| Body Height | 1 | 1992 | 67 | 0.030 |
Why?
|
| Infant | 3 | 2014 | 2891 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2013 | 213 | 0.030 |
Why?
|
| Curriculum | 1 | 1996 | 575 | 0.030 |
Why?
|
| Decision Making | 1 | 2015 | 410 | 0.030 |
Why?
|
| Sheep | 1 | 2011 | 128 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 946 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 1992 | 155 | 0.020 |
Why?
|
| Fractures, Spontaneous | 1 | 1990 | 7 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2012 | 392 | 0.020 |
Why?
|
| Epidemiologic Factors | 1 | 1990 | 2 | 0.020 |
Why?
|
| Metallurgy | 1 | 1990 | 2 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 252 | 0.020 |
Why?
|
| Polysomnography | 1 | 2010 | 92 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1990 | 83 | 0.020 |
Why?
|
| Selection Bias | 1 | 1990 | 23 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 1990 | 57 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1991 | 189 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2009 | 27 | 0.020 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2009 | 8 | 0.020 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 12 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2009 | 82 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2009 | 23 | 0.020 |
Why?
|
| Radiography | 3 | 1997 | 572 | 0.020 |
Why?
|
| Coronary Care Units | 1 | 1988 | 12 | 0.020 |
Why?
|
| Causality | 2 | 2000 | 81 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1994 | 624 | 0.020 |
Why?
|
| Dietary Fats | 2 | 2000 | 103 | 0.020 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1988 | 20 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2009 | 100 | 0.020 |
Why?
|
| Fruit | 2 | 2000 | 86 | 0.020 |
Why?
|
| Vegetables | 2 | 2000 | 76 | 0.020 |
Why?
|
| Aneurysm | 1 | 1988 | 53 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 1994 | 561 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 1990 | 237 | 0.020 |
Why?
|
| Beverages | 1 | 2008 | 50 | 0.020 |
Why?
|
| Biomarkers | 2 | 2006 | 1593 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1985 | 219 | 0.020 |
Why?
|
| Femoral Artery | 1 | 1988 | 139 | 0.020 |
Why?
|
| Physicians | 1 | 2011 | 324 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 1988 | 83 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 1990 | 373 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1988 | 134 | 0.020 |
Why?
|
| Functional Laterality | 1 | 1988 | 240 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2007 | 53 | 0.020 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2006 | 15 | 0.020 |
Why?
|
| Brain Damage, Chronic | 1 | 2006 | 25 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2006 | 23 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 2006 | 55 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1988 | 239 | 0.020 |
Why?
|
| Observer Variation | 2 | 1999 | 330 | 0.020 |
Why?
|
| Brain Infarction | 1 | 2006 | 54 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2006 | 82 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2006 | 87 | 0.020 |
Why?
|
| Marriage | 1 | 1986 | 30 | 0.020 |
Why?
|
| Neuroglia | 1 | 2006 | 136 | 0.020 |
Why?
|
| Thrombin | 1 | 2006 | 117 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 1990 | 1548 | 0.020 |
Why?
|
| Age of Onset | 1 | 2006 | 188 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 1986 | 1533 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 2005 | 33 | 0.020 |
Why?
|
| Methods | 1 | 1985 | 156 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 1987 | 313 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1985 | 80 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2006 | 204 | 0.020 |
Why?
|
| Bioprosthesis | 1 | 1985 | 101 | 0.020 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2003 | 15 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2004 | 25 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2003 | 30 | 0.010 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2003 | 24 | 0.010 |
Why?
|
| Warfarin | 1 | 2004 | 93 | 0.010 |
Why?
|
| Heart Valve Prosthesis | 1 | 1985 | 222 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2006 | 384 | 0.010 |
Why?
|
| Poverty | 1 | 2004 | 218 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2003 | 141 | 0.010 |
Why?
|
| Aspirin | 1 | 2004 | 295 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2005 | 384 | 0.010 |
Why?
|
| Poisson Distribution | 1 | 2001 | 84 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2001 | 47 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 373 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 356 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2002 | 158 | 0.010 |
Why?
|
| Neurons | 1 | 2006 | 881 | 0.010 |
Why?
|
| Models, Neurological | 1 | 2000 | 136 | 0.010 |
Why?
|
| Animals | 3 | 2011 | 20877 | 0.010 |
Why?
|
| Body Fluids | 1 | 1999 | 41 | 0.010 |
Why?
|
| Manikins | 1 | 1999 | 42 | 0.010 |
Why?
|
| Craniotomy | 1 | 1999 | 33 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1999 | 242 | 0.010 |
Why?
|
| Body Temperature | 1 | 1999 | 116 | 0.010 |
Why?
|
| Education, Nursing | 1 | 1999 | 55 | 0.010 |
Why?
|
| Ohio | 1 | 1998 | 64 | 0.010 |
Why?
|
| Vaginal Diseases | 1 | 1978 | 11 | 0.010 |
Why?
|
| Diethylstilbestrol | 1 | 1978 | 45 | 0.010 |
Why?
|
| Models, Economic | 1 | 1998 | 69 | 0.010 |
Why?
|
| Aftercare | 1 | 1999 | 114 | 0.010 |
Why?
|
| Continuity of Patient Care | 1 | 1999 | 170 | 0.010 |
Why?
|
| Sex Distribution | 1 | 1998 | 272 | 0.010 |
Why?
|
| Absenteeism | 1 | 1997 | 27 | 0.010 |
Why?
|
| Age Distribution | 1 | 1998 | 319 | 0.010 |
Why?
|
| Nursing Research | 1 | 1997 | 40 | 0.010 |
Why?
|
| Arthroscopy | 1 | 1997 | 95 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1997 | 328 | 0.010 |
Why?
|
| Patient Readmission | 1 | 1999 | 267 | 0.010 |
Why?
|
| Epilepsy | 1 | 1999 | 336 | 0.010 |
Why?
|
| Sex Factors | 1 | 1998 | 1265 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 1994 | 19 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 2222 | 0.010 |
Why?
|
| Karyotyping | 1 | 1994 | 74 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1994 | 89 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1992 | 48 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1992 | 104 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 852 | 0.010 |
Why?
|
| Proline | 1 | 1992 | 52 | 0.010 |
Why?
|
| Suburban Population | 1 | 1991 | 7 | 0.010 |
Why?
|
| Cost Control | 1 | 1991 | 34 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 1989 | 83 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1988 | 14 | 0.010 |
Why?
|
| Xenon Radioisotopes | 1 | 1988 | 6 | 0.010 |
Why?
|
| Cardiac Complexes, Premature | 1 | 1988 | 4 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 1988 | 104 | 0.010 |
Why?
|
| Tachycardia | 1 | 1988 | 53 | 0.010 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1988 | 73 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 1988 | 110 | 0.010 |
Why?
|
| Probability | 1 | 1988 | 244 | 0.000 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1988 | 182 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1988 | 219 | 0.000 |
Why?
|
| Aorta, Thoracic | 1 | 1988 | 211 | 0.000 |
Why?
|
| Feasibility Studies | 1 | 1988 | 652 | 0.000 |
Why?
|
| Single Person | 1 | 1986 | 5 | 0.000 |
Why?
|
| Endocarditis | 1 | 1985 | 14 | 0.000 |
Why?
|
| Equipment Failure | 1 | 1985 | 112 | 0.000 |
Why?
|
| Mitral Valve | 1 | 1985 | 166 | 0.000 |
Why?
|
| Rats | 1 | 1992 | 5300 | 0.000 |
Why?
|
| Reoperation | 1 | 1985 | 467 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1986 | 799 | 0.000 |
Why?
|
| Aortic Valve | 1 | 1985 | 249 | 0.000 |
Why?
|
| Vaginal Neoplasms | 1 | 1978 | 20 | 0.000 |
Why?
|
| Epithelium | 1 | 1978 | 172 | 0.000 |
Why?
|
| Vagina | 1 | 1978 | 87 | 0.000 |
Why?
|
| Fetus | 1 | 1978 | 157 | 0.000 |
Why?
|
| Pregnancy | 1 | 1978 | 2331 | 0.000 |
Why?
|